New burixafor clinical data to be presented as an oral presentation at the 2025 ash annual meeting

Redwood city, calif., nov. 03, 2025 (globe newswire) -- exicure, inc. (nasdaq: xcur), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed phase 2 study evaluating burixafor, a small molecule cxcr4 antagonist, will be featured in an oral presentation at the 67th american society of hematology (ash) annual meeting and exposition, taking place december 6-9, 2025, in orlando, florida.
ASH Ratings Summary
ASH Quant Ranking